AN Venture Partners

AN Venture Partners is a Tokyo-headquartered venture capital firm focused on early-stage life sciences and biotechnology investing across Japan and the broader Asia-Pacific region. The firm’s mandate concentrates on biotech and pharma therapeutics, reflecting Japan’s strong domestic pharmaceutical industry, academic research base, and government priorities around life sciences innovation. Its positioning is as a specialized investor that bridges Japanese scientific and clinical assets with international syndicates and commercial partners.

AN Venture Partners invests at seed and Series A stages, with typical check sizes in the $5M to $25M range, signaling lead-investor capacity in early institutional rounds. Geographic activity centers on Japan, with extension into the broader Asia-Pacific region and selective participation in cross-border deals involving Japanese research institutions or commercial partners. Deal types include traditional equity investments in early-stage biotech and therapeutic companies, often syndicated alongside US and European life sciences investors when companies pursue international development. The firm tends to take board roles in companies it leads, with active engagement on clinical and corporate strategy.

For founders, AN Venture Partners offers specialized Japanese life sciences capital combined with networks across the country’s pharmaceutical industry and academic research community. The firm is most relevant to biotech and therapeutics teams whose strategies involve Japanese clinical development, partnerships with Japanese pharma, or access to Japanese research collaborators. Founders should expect a rigorous diligence process oriented around scientific and clinical fundamentals, board-level involvement, and engagement on syndicate construction with international co-investors. The firm is best suited to capital-intensive therapeutic programs that benefit from a credible Japanese institutional lead and a multi-round commitment from a specialist life sciences investor.